Study on the efficacy of IFN-γ- and sPD-1-overexpressing BMSCs in enhancing immune effects for the treatment of lung adenocarcinoma

被引:0
|
作者
Xie, Yahui [1 ]
Lv, Zhen [1 ]
Wang, Yubin [2 ]
Ma, Jin [1 ]
Wei, Xingmin [1 ]
Zheng, Guisen [1 ]
Wu, Jianjun [1 ]
机构
[1] Gansu Univ Tradit Chinese Med, Sch Publ Hlth, Lanzhou, Peoples R China
[2] Lanzhou Univ, Hosp 2, Ctr Lab Med, Lanzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
基金
中国国家自然科学基金;
关键词
IFN-gamma; sPD-1; BMSCs; lung adenocarcinoma; immune suppression; CELLS;
D O I
10.3389/fimmu.2025.1554467
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Soluble programmed cell death receptor-1 (sPD-1) blocks the PD-1/PD-L1 pathway, reverses tumor immune suppression, and inhibits tumor growth. However, clinical applications are limited by its poor tissue distribution and rapid dispersion. Bone marrow-derived mesenchymal stem cells (BMSCs) are favorable carriers for tumor immunotherapy due to their capacity for external gene introduction and targeted tumor homing. However, they may inadvertently promote tumor growth. Interferon-gamma (IFN-gamma) inhibits BMSC-mediated tumor growth and stimulates antigen-presenting cells to activate T lymphocytes. This study utilizes BMSCs transfected with IFN-gamma as carriers for sPD-1, enabling the targeted homing of sPD-1 to tumor tissues, thereby enhancing the efficacy and sustained stability of immunotherapy.Methods stable IFN-gamma- and sPD-1-overexpressing BMSCs were successfully constructed by lentiviral transfection. A non-contact co-culture system was established with Lewis and A549 lung adenocarcinoma cells to observe changes in the lung cancer cells after co-culture, using assays including cell migration and invasion experiments, as well as cellular senescence detection. Additionally, a subcutaneous lung adenocarcinoma model was established in C57BL/6J mice for intervention studies. Tumor volume, cellular apoptosis in tumor tissue (assessed by TUNEL assay), peripheral Treg cells (analyzed by flow cytometry), and histopathological markers (evaluated by HE staining and immunohistochemistry) were analyzed. The expression levels of BAX, BCL-2, AKT, PI3K, and PD-L1 were assessed by quantitative PCR and Western Blot.Results IFN-gamma- and sPD-1-overexpressing BMSCs exhibited high bioactivity and genetic stability, inhibiting lung adenocarcinoma cell proliferation, accelerating cellular senescence, and reducing migration and invasion. Furthermore, they upregulate Bax expression, downregulate Bcl-2, and promote apoptosis. Additionally, these cells alleviate inflammatory damage in lung tissue of tumor-bearing mice, lower Treg cell levels to inhibit tumor immune evasion, and reduce the expression of PI3K/AKT and PD-L1.Conclusion IFN-gamma- and sPD-1-overexpressing BMSCs effectively inhibit lung adenocarcinoma cell growth and tumor progression. The primary mechanisms include suppression of cancer cell growth, migration, and invasion; promotion of apoptosis and senescence in cancer cells; modulation of Treg cells; and inhibition of the PI3K/AKT signaling pathway and PD-1/PD-L1 pathways.
引用
收藏
页数:15
相关论文
共 13 条
  • [1] Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
    Chu, Xiangling
    Qiang, Huiping
    Xie, Mengqing
    Li, Xing
    Zhao, Jing
    Wu, Yan
    Zhou, Juan
    Ye, Jinyan
    Zhao, Chao
    Han, Chaonan
    Chu, Tianqing
    Su, Chunxia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1625 - 1631
  • [2] Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
    Xiangling Chu
    Huiping Qiang
    Mengqing Xie
    Xing Li
    Jing Zhao
    Yan Wu
    Juan Zhou
    Jinyan Ye
    Chao Zhao
    Chaonan Han
    Tianqing Chu
    Chunxia Su
    Cancer Immunology, Immunotherapy, 2022, 71 : 1625 - 1631
  • [3] Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study
    Hu, Fang
    Peng, Jin
    Niu, Yanjie
    Mao, Xiaowei
    Zhao, Yizhuo
    Jiang, Liyan
    JOURNAL OF THORACIC DISEASE, 2022, 14 (10)
  • [4] Clinical Study on the Efficacy of Bevacizumab in Combination with Pembrolizumab on Cellular Immune Function in the Treatment of Driver Gene-Negative Stage IV Lung Adenocarcinoma
    Gong, Jun
    Gu, Juanjuan
    Jiang, Lili
    Zhao, Dongxia
    Shao, Lili
    Chen, Xi
    Liu, Jianhua
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [5] Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study
    Huang, Zhe
    Yan, Huan
    Zeng, Liang
    Xu, Qinqin
    Guo, Wenhuan
    Lin, Shaoding
    Jiang, Wenjuan
    Wang, Zhan
    Deng, Li
    Qin, Haoyue
    Zhang, Xing
    Tong, Fan
    Zhang, Ruiguang
    Liu, Zhaoyi
    Zhang, Lin
    Dong, Xiaorong
    Yang, Nong
    Zhang, Yongchang
    JCO PRECISION ONCOLOGY, 2023, 7
  • [6] Efficacy and safety of nintedanib 1 docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Krueger, S.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 618 - 618
  • [7] Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.
    Grohe, Christian
    Blau, Wolfgang
    Gleiber, Wolfgang
    Haas, Siegfried
    Mueller-Huesmann, Harald
    Schulze, Mathias
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455)
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
    Grohe, Christian
    Blau, Wolfgang
    Gleiber, Wolfgang
    Haas, Siegfried
    Krueger, Stefan
    Mueller-Huesmann, Harald
    Schulze, Mathias
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)